Quote this publication Share Print

AFINITOR (everolimus), tyrosine kinase inhibitor

ONCOLOGY - Focus
Opinions on drugs - Posted on Sep 10 2015

Reason for request

Re-assessment of the actual benefit and of the improvement in actual benefit

Minor improvement, in combination with exemestane, in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer

 

  • AFINITOR has Marketing Authorisation, in combination with exemestane, in the treatment of hormone receptor-positive, HER2/neu-negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression of the disease following treatment with a non-steroidal aromatase inhibitor.
  • The combination AFINITOR + AROMASINE(everolimus + exemestane) provides a minor clinical benefit in the treatment of this type of cancer.
  • This combination is integrated into the treatment strategy as adjuvant treatment prior to cytotoxic chemotherapy.

 


Clinical Benefit

Moderate

-


Clinical Added Value

minor

-


Therapeutic use

-

Contact Us

Évaluation des médicaments
All our publications